MIA shines in poster session
22 November 2019
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
PhD student Grace Attrill presented her work on possible biomarkers of response in Stage III melanoma patients treated with anti-PD-1 immunotherapy. She has found that a specific population of immune cell appears in higher numbers in patients who were treated with anti-PD-1 and did not recur. Her research also found that another subpopulation of immune cells may be associated with increased risk of melanoma recurrence. Grace’s poster notes that these immune cells could be a possible biomarker that may indicate which patients will respond well to immunotherapy.
Recent PhD graduate Dr Tuba Nur Gide, also presented a poster on immune cells in melanoma patients treated with immunotherapy. Dr Gide looked at the distribution of specific immune cells in relation to patient response. She found a significant association between response to immunotherapy and a very short distance between immune cells and melanoma cells. A higher amount of these immune cells that were close to patient melanoma cells also related to better progression-free survival for patients on immunotherapy. These findings could also be used to create better biomarkers of patient response.
Another PhD student, Jarem Edwards, presented his research on tumour mutation burden as a possible factor in patient survival. He found that the number of mutations in a patient’s melanoma was not predictive of the amount of immune cells, nor did they predict response or survival in melanoma patients.
Finally, medical oncology fellow, Dr Lalit Pallan, presented his poster on clinical predictors of outcome in melanoma patients with brain metastases treated with combination immunotherapy. Clinicopathological characteristics of patients are those that can be observed by clinicians through minimally invasive techniques such as scans and blood tests. Dr Pallan found that levels of LDH (an enzyme regularly tested for in the blood of melanoma patients), the number of brain metastases, and prior treatments may be factors that could help clinicians determine the likely outcome of treatment. Notably, patients with a lower burden of brain metastases that are asymptomatic and are treated for the first time with combination immunotherapy are more likely to respond to their treatment and have longer progression-free and overall survival.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Ricahrd Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.